LDN in Houston, for autoimmune and inflammatory conditions.
Low-dose naltrexone (compounded, off-label) for selected patients after evaluation — with an honest look at the limited evidence and realistic expectations.
An off-label medication studied in chronic inflammatory conditions.
Low-dose naltrexone (LDN) is a compounded, low-dose preparation of naltrexone — a drug whose standard 50 mg tablets are FDA-approved for opioid and alcohol use disorder — at roughly one-tenth the usual dose. Compounded LDN is not FDA-approved. At the lower dose, naltrexone is thought to act through different pathways involving glial cells, opioid receptor signaling, and inflammatory cytokines; this is still being studied.
LDN has been studied off-label in a number of inflammatory and autoimmune conditions. The evidence is limited: small randomized trials in fibromyalgia, and early or preliminary data elsewhere (such as long COVID and post-viral fatigue). It’s not a miracle drug, and it is not FDA-approved for any of these uses.
Your provider may consider LDN after evaluation, particularly where standard treatments haven’t worked or aren’t appropriate. The off-label nature requires a clinician who understands when to use it and when not to.
Where LDN has been studied.
LDN has been studied in specific patterns of chronic inflammation, autoimmune conditions, and post-viral syndromes. Here’s an honest summary of the evidence.
Autoimmune & inflammatory conditions
Small studies have looked at LDN in conditions such as inflammatory bowel disease and multiple sclerosis; the evidence is limited and benefit has not been established. LDN is often added to existing autoimmune management rather than replacing other treatments. Coordination with the patient’s rheumatologist or specialist is important.
Evidence: Limited · Small studies; not establishedPost-viral fatigue & long COVID
LDN has been discussed for persistent fatigue and other symptoms after COVID-19 or other viral illnesses. Formal trial evidence is preliminary, and benefit has not been established.
Evidence: Preliminary · Trials ongoing · See our immune serviceFibromyalgia & chronic pain
This is where LDN has the most formal trial evidence, though results are mixed: some small randomized studies found less pain than with placebo, while others have not. One proposed mechanism involves glial cells in the central nervous system. For patients whose pain hasn’t responded to standard approaches, LDN may be discussed.
Evidence: Most studied in fibromyalgia · Small RCTs, mixed resultsLDN is one part of addressing the underlying drivers.
When LDN is used, it is one part of a broader approach to inflammation and immune health that addresses root drivers.
Medication is one piece. The foundations matter too.
Chronic inflammation rarely has a single cause. Medication is only one piece; the broader picture matters.
- Sleep quality — chronic poor sleep is one of the strongest drivers of inflammation
- Nutritional foundations — adequate protein, omega-3 status, micronutrient sufficiency
- Stress management — sustained cortisol elevation drives systemic inflammation
- Gut health — coordinated through our immune and gut service
From consultation to first prescription, in real medicine.
LDN requires careful initial dosing and patient education. Side effects are more likely when it is started too high or without adequate context.
Initial consultation
In person at our Houston clinic. We discuss your specific condition, what you’ve tried, current medications (LDN can’t be combined with opioid medications), and your goals. We’re honest about whether LDN is the right tool for your situation or whether something else makes more sense.
Focused workup
Lab work appropriate to your specific concern — thyroid panel, inflammatory markers (CRP, ESR), comprehensive metabolic panel, autoimmune markers where indicated, and other testing based on the suspected underlying condition. The workup tells us what else needs attention alongside LDN.
Treatment plan
If appropriate, compounded LDN (not FDA-approved) at a low starting dose, adjusted gradually by your provider. Your provider explains timing and what to watch for during the initial weeks.
First prescription
Compounded LDN shipped from licensed compounding pharmacy. Detailed instructions from your provider. Clear expectations: any change, if it occurs, is usually gradual, and some patients notice no benefit.
Reassessment
Honest review at 12 weeks. If there is a meaningful response, your provider may continue it. If not, we have an honest conversation about discontinuing — LDN isn’t right for everyone, and we don’t keep prescribing what isn’t working.
Ready to start the conversation?
A 45-minute consultation with one of our Houston providers. We’ll review your specific situation, discuss whether LDN fits your clinical picture, and design a plan that addresses the underlying drivers.
What LDN can — and can’t — do.
LDN may help some patients. It’s also slow-acting and variable in response. Setting expectations matters.
What to know about LDN
- It may be considered off-label for selected patients, such as those with fibromyalgia, after evaluation
- It is used alongside standard care, coordinated with your specialists
- Compounded LDN is not FDA-approved
- It is relatively affordable compared with many specialty medications
- It is reviewed honestly at reassessment and stopped if it isn’t helping
What LDN can’t do
- Be combined with opioid pain medications — absolute contraindication
- Replace primary autoimmune therapy when more aggressive treatment is required
- Produce fast results — any change is usually gradual
- Work for every patient — many patients don’t get a meaningful response
- Avoid initial side effects entirely — vivid dreams and sleep disturbance during the first 1-2 weeks are common but usually resolve
- Be appropriate for patients on opioids (including some pain medications, certain cough suppressants, anti-diarrheal medications)
This page describes a compounded peptide or off-label medication. The compound is not FDA-approved for the proposed indications. Available human clinical evidence is limited. Information on this page is provided for educational purposes; clinical decisions are made individually during provider consultation. See our full disclaimers for additional context.
Before you book.
How much does treatment cost?
Compounded LDN typically runs $30 to $80 per month, which makes it one of the more affordable specialty medications available. Our clinical service fees cover physician oversight, lab review, and structured monitoring separately. We’ll discuss specifics during consultation.
Is LDN FDA-approved?
No. Naltrexone 50 mg tablets are FDA-approved for opioid and alcohol use disorder, but LDN is a compounded preparation, and compounded medications are not FDA-approved. Low-dose use for inflammatory or autoimmune conditions is off-label, meaning the FDA has not reviewed its safety or effectiveness for those uses. Any off-label prescribing is a provider decision after evaluation.
What are the side effects?
The most common initial side effects are vivid or unusual dreams and sleep disturbance during the first 1 to 2 weeks, which typically resolve as the body adjusts. Some patients experience mild headache or GI upset in the first few days. Serious side effects are rare. The biggest practical concern is the contraindication with opioids — LDN blocks opioid receptors, so concurrent opioid use is unsafe.
Can I take LDN with my other medications?
Generally yes, with one critical exception: opioid medications (including some pain medications, certain cough suppressants like codeine, and anti-diarrheal medications like loperamide at higher doses) are absolute contraindications. Your provider checks for interactions with autoimmune medications, antidepressants, and other drugs you take. We review your full medication list during consultation and prescribe accordingly.
How long does it take to work?
Any change, if it occurs, is usually gradual over several weeks, and some patients notice no benefit. Your provider typically reassesses around 12 weeks. Patients expecting fast results often get frustrated — setting realistic expectations upfront matters.
Does it actually work for long COVID?
The honest answer: we don’t know yet. Formal clinical trial evidence is preliminary — long COVID is a relatively new condition, and rigorous LDN trials are ongoing. LDN is not FDA-approved for long COVID, and benefit has not been established. We discuss this honestly during consultation.
What if I’m a non-responder?
Many patients don’t experience meaningful benefit from LDN. If you’ve used it for about 12 weeks without noticeable improvement, we have an honest conversation about whether to continue. Often the answer is acknowledging LDN isn’t the right tool for your situation and exploring other approaches. We don’t keep prescribing if it’s not working.
Start with a conversation, not a prescription.
A 45-minute consultation with one of our Houston providers. We’ll review your specific condition, discuss whether LDN fits, and design a plan that takes the whole picture into account.